Wall Street brokerages predict that Minerva Neurosciences Inc (NASDAQ:NERV) will post earnings per share of ($0.39) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Minerva Neurosciences’ earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.30). Minerva Neurosciences reported earnings of ($0.31) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 25.8%. The business is expected to announce its next quarterly earnings report on Monday, November 4th.

According to Zacks, analysts expect that Minerva Neurosciences will report full year earnings of ($1.51) per share for the current fiscal year, with EPS estimates ranging from ($1.68) to ($1.33). For the next financial year, analysts expect that the business will report earnings of ($2.53) per share, with EPS estimates ranging from ($3.31) to ($1.74). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.10.

A number of research analysts recently commented on NERV shares. BidaskClub raised Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, August 23rd. HC Wainwright began coverage on shares of Minerva Neurosciences in a research note on Friday, May 31st. They set a “buy” rating and a $22.00 price objective on the stock. Zacks Investment Research raised Minerva Neurosciences from a “hold” rating to a “strong-buy” rating and set a $7.75 price objective on the stock in a report on Friday, August 9th. Finally, ValuEngine upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th.

In other news, major shareholder Venture Associates L. Index III sold 197,000 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $6.01, for a total transaction of $1,183,970.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Kupfer bought 10,000 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was acquired at an average price of $5.55 per share, for a total transaction of $55,500.00. Following the acquisition, the director now directly owns 219,188 shares in the company, valued at $1,216,493.40. The disclosure for this purchase can be found here. Insiders sold 438,905 shares of company stock valued at $2,256,214 in the last three months. Insiders own 12.00% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. TD Asset Management Inc. grew its stake in shares of Minerva Neurosciences by 2.8% in the 2nd quarter. TD Asset Management Inc. now owns 58,847 shares of the biopharmaceutical company’s stock valued at $331,000 after buying an additional 1,600 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Minerva Neurosciences by 17.0% during the 4th quarter. Bank of America Corp DE now owns 20,412 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 2,963 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Minerva Neurosciences by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 93,888 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 4,064 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Minerva Neurosciences by 63,940.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,404 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 6,394 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Minerva Neurosciences in the 2nd quarter valued at about $54,000. 74.24% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:NERV traded up $0.68 during trading on Friday, reaching $8.28. 20,038 shares of the company traded hands, compared to its average volume of 218,644. The firm has a market capitalization of $288.79 million, a PE ratio of -6.38 and a beta of 1.54. Minerva Neurosciences has a 52 week low of $4.07 and a 52 week high of $12.95. The company’s 50 day moving average is $6.85 and its two-hundred day moving average is $6.76.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

See Also: Total Return

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.